Therefore, targeting IL-6 could be a potential novel and promising treatment strategy to suppress not only chronic airway but also its associated systemic inflammation, COPD-associated frailty and decline in lung function. This evidence concerns the gene IL6 and chronic obstructive pulmonary disease.